EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Cytomegalovirus DNAemia in Hospitalized Adults With SARS-CoV-2 Infection Requiring Supplemental Oxygen: Virologic and Clinical Characteristics and Association With Outcomes

Michael Boeckh iD, Hu Xie iD, Terry Stevens-Ayers iD, Linda Sircy iD, Danniel Zamora iD, Jason D Goldman iD, Christopher W Woods, Renee D Stapleton, Gordon Rubenfeld, Andre Kalil iD, Keith R Jerome iD, Sayan Dasgupta iD und 1 weitere

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiaf649 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Michael Boeckh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Drug Treatment, Cytomegalovirus, Cytomegalovirus Infections. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Investigator Study.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytomegalovirus (CMV) reactivation occurs in the context of coronavirus disease 2019 (COVID-19); however, the viral kinetics, risk factors, and clinical outcomes are poorly defined.

Methods

We examined the association of CMV DNAemia with clinical outcomes among participants of a randomized trial of remdesivir with or without baricitinib (National Institute of Allergy and Infectious Diseases [NIAID], Adaptive COVID-19 Treatment Trial 2 [ACTT-2]). Plasma CMV DNAemia from CMV-seropositive participants with COVID-19 (NIAID ordinal scale [OS] 5, 6, or 7 at entry) were assessed longitudinally by quantitative polymerase chain reaction. Factors associated with CMV DNAemia, and clinical outcomes were analyzed by Cox regression and proportional odds models.

Results

Of 772 trial participants with available samples, 643 (83%) were CMV seropositive. Baseline CMV serostatus was not associated with COVID-19 outcomes. The cumulative incidence of CMV DNAemia among seropositive persons by day 28 was overall 11% (baseline OS 5, 6.3%; OS 6, 16.4%; OS 7, 24.7%), and was associated with older age, baseline OS, male sex, lymphopenia, and systemic corticosteroid use, while remdesivir and baricitinib did not affect risk. CMV DNAemia was associated with a lower probability of improvement by day 29 (adjusted hazard ratio, 0.3 [95% confidence interval, .17–.56]), with a more pronounced delay of recovery with higher CMV viral load. CMV DNAemia was also associated with higher severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load and death.

Conclusions

In hospitalized adults with COVID-19 requiring oxygen, CMV viremia occurs within well-defined clinical risks and is independently associated with delayed recovery from illness, higher SARS-CoV-2 viral load, and increased mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 Drug TreatmentCytomegalovirusCytomegalovirus InfectionsDNA, ViralOxygen Inhalation TherapyAdultAgedFemaleHumansMaleMiddle AgedAdenosine MonophosphateAlanineAntiviral AgentsHospitalizationPurinesPyrazolesRisk FactorsSARS-CoV-2SulfonamidesTreatment OutcomeViral LoadViremiaAzetidines

Stichwörter der Autor:innen

SARS-CoV-2cytomegalovirusrecoveryviral sheddingviremia

Substanzen

Adenosine MonophosphateAlanineAntiviral AgentsbaricitinibDNA, ViralPurinesPyrazolesremdesivirSulfonamidesAzetidines

Autor:innen und Institutionen

  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Department of Medicine, City of Hope Medical Center, Duarte, California, USA.
  • Infectious Disease, Providence Swedish Medical Center, Seattle, Washington, USA.
  • Division of Infectious Diseases, Center for Precision Health, Duke University, Durham, North Carolina, USA.
  • Department of Medicine, University of Vermont, Burlington, Vermont, USA.

ORCID-Profile: Michael Boeckh, Hu Xie, Terry Stevens-Ayers, Linda Sircy, Danniel Zamora, Jason D Goldman, Andre Kalil, Keith R Jerome, Sayan Dasgupta, Ajit P Limaye

Förderung

  • Merck Investigator Study

Zitieren

APA

Boeckh, M., Xie, H., Stevens-Ayers, T., Sircy, L., Zamora, D., Goldman, J. D., Woods, C. W., Stapleton, R. D., Rubenfeld, G., Kalil, A., Jerome, K. R., Dasgupta, S., & Limaye, A. P. (2025). Cytomegalovirus DNAemia in Hospitalized Adults With SARS-CoV-2 Infection Requiring Supplemental Oxygen: Virologic and Clinical Characteristics and Association With Outcomes. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf649

Vancouver

Boeckh M, Xie H, Stevens-Ayers T, Sircy L, Zamora D, Goldman JD, et al. Cytomegalovirus DNAemia in Hospitalized Adults With SARS-CoV-2 Infection Requiring Supplemental Oxygen: Virologic and Clinical Characteristics and Association With Outcomes. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf649

BibTeX
@article{Boeckh2025,
  author = {Boeckh, Michael and Xie, Hu and Stevens-Ayers, Terry and Sircy, Linda and Zamora, Danniel and Goldman, Jason D and Woods, Christopher W and Stapleton, Renee D and Rubenfeld, Gordon and Kalil, Andre and Jerome, Keith R and Dasgupta, Sayan and Limaye, Ajit P},
  title = {Cytomegalovirus DNAemia in Hospitalized Adults With SARS-CoV-2 Infection Requiring Supplemental Oxygen: Virologic and Clinical Characteristics and Association With Outcomes},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiaf649}
}
Kostenlos starten →